上海利康瑞

Shanghai Likangrui Bio-pharmaceutical Technology is a clinical-stage biotechnology company focused on the development of next-generation cell therapies for oncology. As a core subsidiary of Likang Life Sciences, the company specializes in chimeric antigen receptor T-cell (CAR-T) and TCR-T technologies to treat hematological malignancies and solid tumors. Their lead program, LKR-01, targets CD19-positive B-cell malignancies and has progressed into clinical evaluation. The company operates advanced R&D and manufacturing facilities in Shanghai's Zhangjiang Hi-Tech Park. Likangrui is dedicated to optimizing cell engineering processes to improve the persistence and safety of immunotherapies for cancer patients.